Pipeline Reconciliation Process

Initial BDLive Pipeline Extract

LIMIT RVI TODAY by “Most Recent update” >YEAR(2011)

IF Company = PVIEW “Company” THEN EXCLUDE

IF Drug Name (Or Synonyms) = PVIEW “Drug Name” THEN EXCLUDE

IF Phase > then Pregesitration (e.g. Launched) THEN EXCLUDE

ELSE ADD

File	Modified
Combined Pipeline Mapping File_18 08 2014.xlsx	Aug 18, 2014 by Duncan, Ben
BDLive Pipeline Fields 07-15-14.pptx	Jul 17, 2014 by Merseth, Andrew

Drag and drop to upload or

browse for files

Download All

Process Steps (Kentico)

1. Extract PV pipeline drugs only (from superset?) - in Phase column, exclude 'Launched' drugs, leaving Approved, Filed, Phase III, Phase II, Phase I
2. In BDLive pipeline dataset, map Phases to PV Phases (Phase I, 2, 3, Filed, Approved)
3. For top-47 companies only, exclude drugs from BDLive when BDLive company name = PV company name
    a. Q: Include step here to check excluded drugs for non drug name matches, in order to see if we have missed drugs that we need to add back into our model, or at least look into?
4. For all PV companies outside top-47, check for brand / molecule name / research code matches between PV and BDLive; when there is a match, exclude from BDLive dataset
5. For remaining drugs, determine highest development phase indication(s) by:
    a. If multiple indications each with different phases, select indication with highest phase
    b. If multiple indications, any of which has the same phase, combine indications into a single row (e.g. diabetes / rheumatoid arthritis)
    c. If single indication, no change needed
6. For this smaller BDLive dataset, using predetermined TA and Drug Group > Specific Relay Indication mappings, populate the PV TA and PV Drug Group columns for BDLive drugs.
    a. Q: TBD whether we can use a different method for helping analysts assign individual drugs to Oncology drug groups (e.g. can we identify drugs in BDLive as being 'Biologics', 'Targeted Small Molecules', 'Cytotoxics' etc)?
    b. If not, we will not be able to supplement the Oncology drug group reports with BDLive pipeline data

Process Steps (Dashboard)

1. Extract PV pipeline drugs only (from superset?) - in Phase column, exclude 'Launched' drugs, leaving Approved, Filed, Phase III, Phase II, Phase I
2. In BDLive pipeline dataset, map Phases to PV Phases (Phase I, 2, 3, Filed, Approved)
3. For top-47 companies only, exclude drugs from BDLive when BDLive company name = PV company name

    a. Q: Include step here to check excluded drugs for non drug name matches, in order to see if we have missed drugs that we need to add back into our model, or at least look into?
4. For all PV companies outside top-47, check for brand / molecule name / research code matches between PV and BDLive; when there is a match, exclude from BDLive dataset
5. For PVP drugs, match specific drug name / indication / phase combinations to identify highest dev phase captured in PVP
    a. Exclude these matches from BDLive dataset, but keep all non matches (we want to present additional detail of multiple indications in dashboard i presume, in which case we need to add back the indications we're missing in PVP
6. For this smaller BDLive dataset, using predetermined TA and Drug Group > Specific Relay Indication mappings, populate the PV TA and PV Drug Group columns for BDLive drugs.
    a. Q: TBD whether we can use a different method for helping analysts assign individual drugs to Oncology drug groups (e.g. can we identify drugs in BDLive as being 'Biologics', 'Targeted Small Molecules', 'Cytotoxics' etc)?
7. Others?